Companies
Eli Lilly signs cancer drug deal with Stipple Bio
Eli Lilly licensed cancer research from private biotech Stipple Bio in a deal that widens Lilly's cancer pipeline. Stipple could earn milestone payments and royalties if the drugs clear research and sales goals.
Quick Read
- Eli Lilly signed a research and licensing deal with private biotech Stipple Bio to develop targeted cancer drugs.
- Stipple could earn milestone payments and royalties, and receives an upfront payment and equity investment whose amounts were not disclosed.
- Lilly secures exclusive worldwide rights to any products the partnership produces.
- Lilly shares fell on Tuesday along with the broad market, and the company separately agreed to acquire Calytrix Bio.

What did Eli Lilly agree to?
Eli Lilly (NYSE: LLY) signed a research and licensing deal on Monday with Stipple Bio, a privately held biotech, to develop targeted cancer drugs. The deal covers a range of drug targets and treatment approaches.
Why it matters: Under the agreement, Stipple could receive up to $5.9 billion in milestone payments. Those are sums paid only when a drug reaches set research, development or sales goals. Lilly also makes an upfront payment and an equity investment, buying a stake in Stipple. The companies did not disclose those amounts.
In return, Lilly secures exclusive worldwide rights to develop and sell any products the collaboration produces. Stipple could also earn tiered royalties, a cut of sales whose rate changes with sales levels.
What does Stipple bring to the deal?
Stipple uses its own Pointillist Platform to find molecules that attach to specific sites on the surface of tumor cells, called epitopes. Lilly plans to pair those finds with its own cancer technologies.
The aim is drugs that work better against tumors while sparing healthy tissue. That kind of damage to healthy tissue has historically limited the use of some cancer drug targets.
Stipple CEO Jeff Landau said Lilly's cancer research and drug development experience could help advance more precise treatments. He said Stipple would keep developing its own drugs.
Stipple's most advanced drug is STP-100, an antibody-drug conjugate: an antibody that carries a drug directly to tumor cells. The company plans an early-stage clinical trial in early 2027 in solid tumors, including pancreatic cancer.
How did Lilly shares trade?
Lilly shares slid 1.1% on Tuesday, closing at $1,415.55. The company lost $15 billion in market value and sits 1.9% below its 52-week high of $1,443.50.
The drop came on a broad down day. The S&P 500 slid 1.0%, and the health care sector fund fell 1.4%. No source tied Lilly's drop to the Stipple deal.
Lilly accounts for 1.5% of the combined value of the 500 largest U.S. companies, so its drop took $17 from $100,000 spread across them by size.
Separately, Lilly agreed on Monday to acquire Calytrix Bio for up to $1.5 billion in cash.
For readers
What it could mean for you: If you own Lilly shares directly, this deal reaches you through the company's spending and its future cancer drug lineup. Milestone payments are owed only as drugs clear research, development and sales goals, so the full cost may arrive slowly or not at all. Stipple's planned early-stage trial of STP-100 in early 2027 may give an early read on whether its approach works in patients. Results like that could shape how investors value Lilly's cancer pipeline over time.
Questions and answers
How much is the Eli Lilly and Stipple Bio deal worth?
Under the agreement, Stipple could receive up to $5.9 billion in milestone payments, plus royalties on any sales. Lilly also makes an upfront payment and an equity investment, but the companies did not disclose those amounts.
What does Stipple Bio do?
Stipple is a privately held biotech that uses its Pointillist Platform to find molecules that attach to specific sites on tumor cells. Its most advanced drug, STP-100, is an antibody-drug conjugate aimed at solid tumors, including pancreatic cancer.
What rights does Eli Lilly receive under the Stipple deal?
Lilly secures exclusive worldwide rights to develop and sell products that come out of the collaboration. Stipple could earn tiered royalties if Lilly brings those therapies to market.
What is the Eli Lilly deal for Calytrix Bio?
Lilly agreed on Monday to acquire Calytrix Bio for up to $1.5 billion in cash. It is a separate transaction from the Stipple agreement.
The numbers
| Eli Lilly (LLY) price | $1,415.55 |
|---|---|
| Eli Lilly (LLY) change | −1.13% |
| Eli Lilly (LLY) market value | $1.3 trillion |
| Eli Lilly (LLY) 52-week high | $1,443.50 |
| S&P 500 change | −1.03% |
| 10-year Treasury yield | 5.10% |
Tuesday’s close
Companies in this story
Share this story
Not investment advice.


